SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Vorapaxar

Item No. 23119



CAS Registry No.:	618385-01-6
Formal Name:	N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl] dodecahydro-1-methyl-3-oxonaphtho[2,3-c] furan-6-yl]-carbamic acid, ethyl ester
MF:	$C_{29}H_{33}FN_2O_4$
FW:	492.6
Purity:	≥98%
UV/Vis.:	λ_{max}: 272, 306 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vorapaxar is supplied as a crystalline solid. A stock solution may be made by dissolving the vorapaxar in the solvent of choice. Vorapaxar is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of vorapaxar in these solvents is approximately 30 mg/ml.

Vorapaxar is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, vorapaxar should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Vorapaxar has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Vorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor (PAR1; K_i = 8.1 nM), also known as the thrombin receptor.[1] It is selective for PAR1 over other PARs, as well as a number of GPCRs, ion channels, and receptors. It inhibits platelet aggregation induced by thrombin (Item No. 13188) and haTRAP (IC_{50}s = 47 and 25 nM, respectively). Vorapaxar (0.1 mg/kg, i.v.) completely inhibits platelet aggregation in cynomolgus monkeys *ex vivo*. Formulations containing vorapaxar are used in the prevention of thrombotic cardiovascular events.

Reference

1. Chackalamannil, S., Wang, Y., Greenlee, W.J., *et al.* Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. *J. Med. Chem.* **51(110)**, 3061-3064 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM